3 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Granuloma: new trials by email Literature Review of Granuloma trials Research Report on Granuloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
Churg-Strauss Syndrome (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Granulomatosis with Polyangiitis (1) · Lupus Nephritis (1) · Microscopic Polyangiitis (1) · Vasculitis (1)
Autoimmune Diseases (3) · Cardiovascular Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Systemic Vasculitis (3) · Vascular Diseases (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Vasculitis (2) · Brain Diseases (1)
tezepelumab (1)
Alpine Immune Sciences, Inc. (1) · Imperial College London (1) · NS Pharma, Inc. (1)
United Kingdom (2) · United States (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Spain (1)